NCT07502209 Notch vs Midpoint Suprascapular Nerve PRF for Chronic Shoulder Pain
| NCT ID | NCT07502209 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ankara City Hospital Bilkent |
| Condition | Chronic Shoulder Pain |
| Study Type | INTERVENTIONAL |
| Enrollment | 32 participants |
| Start Date | 2026-05-07 |
| Primary Completion | 2027-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 32 participants in total. It began in 2026-05-07 with a primary completion date of 2027-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to compare the effects of pulsed radiofrequency (PRF) treatment of the suprascapular nerve using suprascapular notch and midpoint approaches on pain, shoulder function, and muscle strength in patients with chronic shoulder pain due to rotator cuff tendinopathy. Patients will be randomly assigned to one of the two intervention groups. Clinical evaluations will include pain assessment using the Numeric Rating Scale (NRS), functional assessment using the Shoulder Pain and Disability Index (SPADI), and quality of life assessment using the Short Form-36 (SF-36). In addition, shoulder range of motion will be measured goniometrically, muscle thickness of the supraspinatus and infraspinatus will be evaluated by ultrasonography, and shoulder muscle strength will be assessed using an isokinetic dynamometer. Assessments will be performed at baseline, 24 hours, 1 month, and 3 months after the intervention. The results of this study are expected to provide evidence regarding the optimal approach for PRF treatment of the suprascapular nerve in patients with chronic shoulder pain.
Eligibility Criteria
Inclusion Criteria: * Patients aged between 40 and 80 years * Patients with chronic shoulder pain lasting longer than 3 months * Patients diagnosed with rotator cuff-related shoulder pain * Patients who show at least 50% pain reduction after diagnostic suprascapular nerve block * Patients who provide written informed consent Exclusion Criteria: * Adhesive capsulitis * Previous shoulder surgery * Full-thickness rotator cuff tear * Neurological disorders affecting the shoulder * Pacemaker * Coagulopathy or anticoagulant therapy contraindicating intervention * Infection at the injection site * Severe systemic disease * Pregnancy * Inability to comply with study protocol
Contact & Investigator
Ayşe Merve Ata, MD
PRINCIPAL INVESTIGATOR
Ankara City Hospital Bilkent
Frequently Asked Questions
Who can join the NCT07502209 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, up to 80 Years, studying Chronic Shoulder Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07502209 currently recruiting?
Yes, NCT07502209 is actively recruiting participants. Contact the research team at gulberk.koc95@gmail.com for enrollment information.
Where is the NCT07502209 trial being conducted?
This trial is being conducted at Ankara, Turkey (Türkiye).
Who is sponsoring the NCT07502209 clinical trial?
NCT07502209 is sponsored by Ankara City Hospital Bilkent. The principal investigator is Ayşe Merve Ata, MD at Ankara City Hospital Bilkent. The trial plans to enroll 32 participants.